Get the Stockscreener App
0.651
2.59%
-0.0137
Adaptimmune Therapeutics Plc Adr stock is traded at $0.651, with a volume of 217.31K.
It is down -2.59% in the last 24 hours and down -21.40% over the past month.
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
See More
Previous Close:
$0.6647
Open:
$0.66
24h Volume:
217.31K
Relative Volume:
0.15
Market Cap:
$172.06M
Revenue:
$175.04M
Net Income/Loss:
$-44.52M
P/E Ratio:
-1.2196
EPS:
-0.5338
Net Cash Flow:
$-56.05M
1W Performance:
+9.52%
1M Performance:
-21.40%
6M Performance:
-40.05%
1Y Performance:
+46.66%
1-Day Range:
$0.645
$0.6825
1-Week Range:
$0.571
$0.705
52-Week Range:
$0.4205
$2.05
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
Name
Adaptimmune Therapeutics Plc Adr
Sector
Industry
Phone
44 1235 430000
Address
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Compare ADAP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ADAP | 0.6497 | 172.06M | 175.04M | -44.52M | -56.05M | -0.5338 |
| VRTX | 446.54 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 737.53 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 585.04 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.28 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.20 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-09-22 | Upgrade | Mizuho | Neutral → Buy |
| May-28-21 | Initiated | Barclays | Underweight |
| Apr-22-20 | Initiated | Mizuho | Neutral |
| Aug-02-19 | Downgrade | Guggenheim | Buy → Neutral |
| May-31-19 | Initiated | ROTH Capital | Buy |
| May-30-19 | Resumed | Citigroup | Buy |
| May-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-17-17 | Initiated | Wells Fargo | Market Perform |
| Oct-24-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Sep-30-16 | Initiated | Raymond James | Outperform |
| Feb-25-16 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | BofA/Merrill | Neutral |
| Jun-01-15 | Initiated | Guggenheim | Buy |
| Jun-01-15 | Initiated | Leerink Partners | Outperform |
View All
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Latest News
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register
Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register
Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa
Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com
Adaptimmune faces Nasdaq delisting over share price - Investing.com India
NVIDIA Corp (NVDA): Be Patient, You Will Learn - Stocks Register
Investing in HUYA Inc ADR (HUYA): What You Must Know - Knox Daily
Checking in on Blackstone Inc (BX) after recent insiders movement - Knox Daily
Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News
Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily
The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle
Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News
Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
A significant driver of top-line growth: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Analysts review Adaptimmune Therapeutics Plc ADR’s rating - Knox Daily
How should investors view Adaptimmune Therapeutics Plc ADR (ADAP)? - US Post News
Recent Insider Activity Could Benefit Zentalis Pharmaceuticals Inc (ZNTL) - Knox Daily
Wall Street SWOT: Adaptimmune stock faces challenges despite FDA win - Investing.com
Stocks of Adaptimmune Therapeutics Plc ADR (ADAP) are poised to climb above their peers - SETE News
Insider Sale Alert: Gap, Inc. [GAP] – Is it Time to sell? - Knox Daily
Adaptimmune Therapeutics Plc ADR [ADAP] Piccina Cintia sells 24,531 Shares for $22814.0 - Knox Daily
Adaptimmune finalizes settlement with Genentech - Investing.com India
ADAP’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Ratios Uncovered: Breaking Down Adaptimmune Therapeutics Plc ADR (ADAP)’s Trailing Twelve Months Metrics - The Dwinnex
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Yahoo Finance UK
Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance: Is It Undervalued or Overvalued? - The InvestChronicle
Recent Insider Activity Could Benefit Adaptimmune Therapeutics Plc ADR (ADAP) - Knox Daily
Zumiez Inc’s latest rating changes from various analysts - Knox Daily
AdaptHealth Stock Earns RS Rating Upgrade - MSN
A new trading data show Adaptimmune Therapeutics Plc ADR (ADAP) is showing positive returns. - SETE News
Predicting Adaptimmune Therapeutics Plc ADR’s (ADAP) earnings for the current quarter - US Post News
Director SIMON WILLIAM E JR acquire 45,000 shares of Douglas Emmett Inc [DEI] - Knox Daily
Buying Buzz: Noble Corp Plc [NE] 10% Owner APMH Invest A/S purchases 324,984 shares of the company - Knox Daily
There is no doubt that Adaptimmune Therapeutics Plc ADR (ADAP) ticks all the boxes. - SETE News
Analyzing Ratios: Adaptimmune Therapeutics Plc ADR (ADAP)’s Financial Story Unveiled - The Dwinnex
Adaptimmune Therapeutics Plc ADR (ADAP) stock analysis: A simple moving average approach - US Post News
A company insider recently sold 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP]. Should You Sale? - Knox Daily
EWCZ Shares Experience Decline in Value - Knox Daily
Natera Inc [NTRA] Shares Jump Approximately 97.71% Over the Year - Knox Daily
Adaptimmune Therapeutics Plc ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Premier Inc [PINC] Shares Fall -1.35 % on Thursday - Knox Daily
An analyst sees good growth prospects for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Closing Figures: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.16, Down -4.13 - The Dwinnex
Analyzing Adaptimmune Therapeutics Plc ADR (ADAP) After Recent Trading Activity - Knox Daily
Adaptimmune Therapeutics Plc ADR (ADAP) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Market Recap Check: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.24, Up/Down -6.77 - The Dwinnex
Adaptimmune Therapeutics Plc ADR: Rising -35.12% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
A closer look at Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price trends - US Post News
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):